The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.
For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.
Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.
Careers
We look for the best and brightest of tomorrow and develop careers from the ground up.
Leading Matters
Client Highlights
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
Firm Advises hyperexponential on Acquisition by Guidewire for up to $2.1 Billion
On October 27, 2026, Guidewire, a cloud platform for P&C insurers, announced that it entered into a definitive agreement to acquire hyperexponential, a London-based agentic platform provider of AI-native underwriting and pricing software for commercial lines P&C insurers, for a base purchase price of $1.7 billion in cash, subject to adjustments. The agreement also includes up to an additional $400 million in contingent consideration based on achievement of specified recurring revenue targets, bringing the total deal value to up to $2.1 billion and marking the transaction as the largest-ever M&A exit of a privately held, venture-backed UK technology company. hyperexponential is an existing Guidewire PartnerConnect Technology Alliance Partner and brings established trust and scale in underwriting, having powered underwriting decisions across more than $75 billion in annual commercial P&C premium for leading global insurers, reinsurers, and managing general agents. Wilson Sonsini Goodrich & Rosati advised hyperexponential on the transaction.
Client Highlights
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Prana Therapies on IP Matters Related to Acquisition by Bolt Biotherapeutics
On October 23, 2026, Bolt Biotherapeutics, a clinical-stage biotechnology company, announced the acquisition of Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, Bolt Biotherapeutics will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. Wilson Sonsini Goodrich & Rosati advised Prana Therapies on the intellectual property matters related to the transaction.
Client Highlights
Wilson Sonsini Advises Otter.ai on $320 Million Growth Investment
On October 20, 2026, Otter.ai, the company behind the leading AI notetaker and conversational knowledge platform, announced $320 million in growth financing from General Catalyst's Customer Value Fund. Wilson Sonsini Goodrich & Rosati advised Otter.ai on the transaction.
Client Highlights
Wilson Sonsini Advises ElevenLabs on $300 Million Employee Tender Offer
On September 30, 2026, ElevenLabs, a voice technology research company, announced the closing of a $300 million employee tender offer that values the company at $22 billion, doubling its valuation at its Series D financing in February 2026. The tender offer was led by Wellington and T. Rowe Price, with participation from new investors BDT & MSD, EQT, GIC, Goldman Sachs, OTPP, and Sapphire Ventures, as well as existing investors including Alkeon, Andreessen Horowitz, D.E. Shaw, DISRUPTIVE, Evantic, ICONIQ, and Lightspeed. Wilson Sonsini Goodrich & Rosati advised Elevenlabs on the transaction.
The Life Sciences Report – June 2026
This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.